XML 91 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events (Details)
 1 Months Ended
Oct. 01, 2023
USD ($)
shares
Sep. 06, 2023
USD ($)
Sep. 06, 2023
TWD ($)
Apr. 16, 2022
$ / shares
Oct. 31, 2021
USD ($)
Oct. 15, 2021
$ / shares
Oct. 15, 2021
$ / shares
Sep. 06, 2021
USD ($)
Sep. 06, 2021
TWD ($)
Nov. 30, 2023
Feb. 23, 2023
USD ($)
$ / shares
shares
Apr. 16, 2022
$ / shares
Sep. 30, 2023
shares
 [1]
Jul. 14, 2023
USD ($)
Jan. 14, 2023
TWD ($)
Jan. 03, 2023
shares
Dec. 31, 2022
shares
 [1]
Sep. 06, 2022
USD ($)
Sep. 06, 2022
TWD ($)
Jun. 29, 2021
shares
May 17, 2021
$ / shares
Subsequent Events [Line Items]                                          
Common shares, issued (in Shares) | shares                         4,823,043     223,411 3,286,190     50,000  
Principal amount                                   $ 243,750 $ 7,500,000    
Principle amount   $ 232,500 $ 7,500,000   $ 650,000     $ 243,750 $ 7,500,000                        
Initial conversion price (in Dollars per share) | $ / shares                                         $ 2.25
Common stock , exercise price (in Dollars per share) | $ / shares       $ 3   $ 3 $ 3         $ 3                  
Subsequent Event [Member]                                          
Subsequent Events [Line Items]                                          
Purchase shares (in Shares) | shares 2,329,495                                        
Purchase agreement executed $ 1,572,600                                        
Subsequent event description                   the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entered into a multi-year, global licensing agreement with AIBL for the Company and BioLite’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The potential license will cover the Licensed Products’ clinical trial, registration, manufacturing, supply, and distribution rights. The Licensed Products for MDD and ADHD, owned by ABVC and BioLite, were valued at $667M by a third-party evaluation. The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the respective agreements, each of ABVC and BioLite shall receive 23 million shares of AIBL stock at $10 per share, and if certain milestones are met, $3,500,000 and royalties equaling 5% of net sales, up to $100 million.                      
Common shares, issued (in Shares) | shares                               223,411          
Principal amount                             $ 20,000,000            
Forecast [Member]                                          
Subsequent Events [Line Items]                                          
Principal amount                           $ 650,000              
Lind Global Fund II [Member] | Subsequent Event [Member]                                          
Subsequent Events [Line Items]                                          
Principle amount                     $ 3,704,167                    
Purchase price                     $ 3,175,000                    
Initial conversion price (in Dollars per share) | $ / shares                     $ 1.05                    
Common stock , exercise price (in Dollars per share) | $ / shares                     $ 1.05                    
Lind Global Fund II [Member] | Forecast [Member]                                          
Subsequent Events [Line Items]                                          
Purchase warrants (in Shares) | shares                     5,291,667                    
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.